- Home
- KOD vs HQL Comparison
KOD vs HQL Comparison
Compare KOD & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- HQL
- Stock Information
- Founded
- KOD 2009
- HQL 1992
- Country
- KOD United States
- HQL United States
- Employees
- KOD N/A
- HQL N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- HQL Investment Managers
- Sector
- KOD Health Care
- HQL Finance
- Exchange
- KOD Nasdaq
- HQL Nasdaq
- Market Cap
- KOD 454.7M
- HQL 372.7M
- IPO Year
- KOD 2018
- HQL N/A
- Fundamental
- Price
- KOD $4.45
- HQL $13.85
- Analyst Decision
- KOD Hold
- HQL
- Analyst Count
- KOD 4
- HQL 0
- Target Price
- KOD $8.00
- HQL N/A
- AVG Volume (30 Days)
- KOD 347.2K
- HQL 120.9K
- Earning Date
- KOD 03-27-2025
- HQL 01-01-0001
- Dividend Yield
- KOD N/A
- HQL 11.56%
- EPS Growth
- KOD N/A
- HQL N/A
- EPS
- KOD N/A
- HQL 0.79
- Revenue
- KOD N/A
- HQL N/A
- Revenue This Year
- KOD N/A
- HQL N/A
- Revenue Next Year
- KOD N/A
- HQL N/A
- P/E Ratio
- KOD N/A
- HQL $17.08
- Revenue Growth
- KOD N/A
- HQL N/A
- 52 Week Low
- KOD $2.19
- HQL $11.34
- 52 Week High
- KOD $11.60
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- KOD 27.56
- HQL 46.39
- Support Level
- KOD $4.85
- HQL $13.66
- Resistance Level
- KOD $5.53
- HQL $14.41
- Average True Range (ATR)
- KOD 0.39
- HQL 0.20
- MACD
- KOD -0.05
- HQL -0.01
- Stochastic Oscillator
- KOD 1.03
- HQL 24.34
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.